Neuphoria Net Income from 2010 to 2025

NEUP Stock   3.72  0.07  1.85%   
Neuphoria Therapeutics Net Loss yearly trend continues to be relatively stable with very little volatility. Net Loss is likely to drop to about -594.1 K. During the period from 2010 to 2025, Neuphoria Therapeutics Net Loss destribution of quarterly values had r-value of (0.22) from its regression line and median of (8,646,819). View All Fundamentals
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
-565.8 K
Current Value
-594.1 K
Quarterly Volatility
9.5 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Neuphoria Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Neuphoria Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.1 M, Interest Expense of 15.4 K or Other Operating Expenses of 17.8 M, as well as many indicators such as Price To Sales Ratio of 0.41, Dividend Yield of 0.0 or PTB Ratio of 6.0E-4. Neuphoria financial statements analysis is a perfect complement when working with Neuphoria Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Neuphoria Stock
Check out the analysis of Neuphoria Therapeutics Correlation against competitors.
To learn how to invest in Neuphoria Stock, please use our How to Invest in Neuphoria Therapeutics guide.

Pair Trading with Neuphoria Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Neuphoria Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Neuphoria Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Neuphoria Stock

  0.81RAC Race OncologyPairCorr
  0.85VALN Valneva SE ADRPairCorr

Moving against Neuphoria Stock

  0.7VCEL Vericel Corp OrdPairCorr
  0.64VCYT VeracytePairCorr
  0.56VKTX Viking TherapeuticsPairCorr
  0.53DSGN Design TherapeuticsPairCorr
  0.52DVAX Dynavax Technologies TrendingPairCorr
The ability to find closely correlated positions to Neuphoria Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Neuphoria Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Neuphoria Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Neuphoria Therapeutics to buy it.
The correlation of Neuphoria Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Neuphoria Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Neuphoria Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Neuphoria Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Neuphoria Stock Analysis

When running Neuphoria Therapeutics' price analysis, check to measure Neuphoria Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neuphoria Therapeutics is operating at the current time. Most of Neuphoria Therapeutics' value examination focuses on studying past and present price action to predict the probability of Neuphoria Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neuphoria Therapeutics' price. Additionally, you may evaluate how the addition of Neuphoria Therapeutics to your portfolios can decrease your overall portfolio volatility.